Clinical Research Directory
Browse clinical research sites, groups, and studies.
TWEAK, a New Biomarker for Predicting Inflammatory Relapses in Multiple Sclerosis
Sponsor: Assistance Publique Hopitaux De Marseille
Summary
A significant variation in the serum concentration of the circulating cytokine TWEAK is associated with the onset of an inflammatory attack of MS. Study the concentration variations of the serum soluble form of cytokine TWEAK during the first year of MS and to analyze their correlation with the occurrence of an inflammatory disease outbreak.
Official title: TNF-related Weak Inducer of Apoptosis (TWEAK), a New Biomarker Predicting Inflammatory Thrust in Multiple Sclerosis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2023-06-16
Completion Date
2027-06-16
Last Updated
2026-09-23
Healthy Volunteers
No
Conditions
Interventions
Determination of the circulating serum concentration of cytoquine TWEAK
Blood samples (20 ml of blood on dry tube) by venipuncture at the bend of the elbow will be made at T0, then monthly for a period of 1 year . The sera will be isolated by centrifugation and then frozen at -80 degrees Assays of the soluble form of TWEAK and TNF will be performed by ELISA blot technique developed by the team.
Locations (1)
Assistance Publique Hopitaux de Marseille
Marseille, France